Asthma Flashcards

1
Q

Why is asthma important?

A

-Common
-Kills people
-Can recognise, control and fix disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Factors that predispose asthma not resolving in adolescence/ returning later in life

A

-Airway hyperresponsiveness
-Sensitisation to house dust mite
-Female sex
-Smoking at age 21

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe genetic risk asthma

A

-Atopy
=Increased allergic hypersensitivity (inhaled allergens)
=Often have raised IgE and positive skin prick tests
=Atopic dermatitis and allergic rhinitis (IgE mediated)
=May also be sensitive to aspirin, nasal polyps

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe environmental risk factors for asthma

A

-Influence susceptibility to development of asthma in predisposed individuals
-Precipitate asthma exacerbations

-Allergens
-Hygiene hypothesis
=Exposure to infections early in life influences immune system along non-allergic pathway
-Antenatal factors: maternal smoking, viral infection during pregnancy (especially RSV)
-Low birth weight
-Not being breastfed
-Maternal smoking around child
-Exposure to high concentrations of allergens (e.g. house dust mite)
-Air pollution

-Occupation (bakery, construction…)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Pathophysiology of asthma

A

-Chronic inflammatory disorder of the airways secondary to type 1 hypersensitivity
-Th2 lymphocyte driven
-Many cells and cellular elements play role
=Eosinophils (IL-5 from Th2 stimulated)
=Mast cells (releases histamine, leukotrienes, cytokines)
=B cells (produce IgE to stimulate mast cell)
=Neutrophils

-Increased mucus production
-Bronchospasm/ constriction
-Swelling and irritation of airways

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How does inflammation manifest in asthma?

A

-Increased hyper-responsiveness
=Acute bronchoconstriction= turbulent airflow= wheeze

-Swelling of airway (increased permeability of airway)

-Mucus plug formation (goblet cell hypersecretion)

-Airway wall remodelling/ thickening of basement membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Asthma history

A

-Presence of more than one variable symptom of wheeze, cough, breathlessness, and chest tightness.
=Symptoms are commonly episodic, diurnal (worse at night or in the early morning), and/or triggered or exacerbated by exercise, viral infection, and exposure to cold air or allergens.
=In children, symptoms may also be triggered by emotion and laughter.
=In adults, symptoms may be triggered by use of non-steroidal anti-inflammatory drugs and beta-blockers.
=Ideally, expiratory polyphonic wheeze (with multiple pitches and tones heard over different areas of the lung when the person breathes out) will be confirmed on auscultation.
=Note: Occupational asthma may be suggested by adult-onset asthma, where symptoms improve when not at work. High-risk occupations include laboratory work, baking, animal handling, welding, and paint spraying. Check for possible occupational asthma by asking:
==Are symptoms better on days away from work?
==Are symptoms better when on holiday?

-Personal/family history of other atopic conditions, particularly atopic eczema/dermatitis and/or allergic rhinitis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do we diagnose asthma?

A

-Breathlessness
-Cough (often worse at night)
-Wheeze (expiratory on auscultation)/ chest tightness

-Variable airflow obstruction
=Spirometry initial test (presence and severity)
==FEV1 significantly reduced, FVC normal, FEV1% <70
-PEF if spirometry not available- reduced PEFR
=Fractional inhaled nitric oxide FeNO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

FeNO testing

A

should be used where possible to confirm eosinophilic airway inflammation to support an asthma diagnosis in people aged 17 years and older. This test may be available in some primary care practices or may require referral to a specialist centre. In steroid-naive adults, a FeNO level of 40 parts per billion (ppb) or higher is considered a positive result.
=Consider FeNO testing in children and young people (aged 5 to 16 years) if there is diagnostic uncertainty after initial assessment, and they have either normal spirometry or obstructive spirometry with a negative bronchodilator reversibility (BDR) test (see below). A FeNO level of 35ppb is considered a positive result in this group.
==Approximately 1 in 5 people with a negative result will have asthma.
==Approximately 1 in 5 people with a positive result will not have asthma.
==Be aware that the results of FeNO tests may be affected by empirical treatment with inhaled corticosteroids.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Provoking factors for asthma

A

-Inhaled aeroallergens
-Exercise
-Anxiety/ stress
-Temperature change
-Cigarette smoke
-Foods, additives (preservatives, colouring agents)
-Occupational agents (isocyanates)
-Drugs (NSAIDs, b blockers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Features that increase the probability of asthma

A

-1+ of the following
=Wheeze, breathlessness, chest tightness, cough (worse at night and early morning/ response to exercise, allergen exposure and cold air/ after taking aspirin or b blockers/ family history of asthma or atopy)

=Widespread wheeze heard on auscultation of the chest

=Unexplained low FEV1 or PEF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Features that lower probability of asthma

A

-Prominent dizziness, light-headedness, peripheral tingling
-Chronic productive cough in the absence of wheeze or breathlessness
-Repeatedly normal physical examination of chest when symptomatic
-Voice disturbance
-Symptoms with colds only (bronchial hyperactivity syndrome)
-Significant smoking history (>20 pack-years)
-Cardiac disease
-Normal PEF or spirometry when symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How to test for airflow obstruction

A
  1. Basic spirometry
    =Reduction in FEV1
    =FEV1: FVC ratio less than 70%
  2. Reversibility testing/ treatment trials
    =Nebulized bronchodilators (or steroids)
    ->400mls improvement/ symptom scores
    =in adults, a positive test is indicated by an improvement in FEV1 of 12% or more and increase in volume of 200 ml or more
    =in children, a positive test is indicated by an improvement in FEV1 of 12% or more
  3. Monitor peak flow/ PEF monitoring- variability 20% after monitoring at least twice daily for 2-4 weeks is regarded as a positive result
  4. Assessment airway responsiveness
    =Useful in patients with normal lung function
    =Histamine challenge= induce bronchoconstriction
  5. CXR, blood eosinophil, IgE, skin prick tests
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Diagnosis algorithm in asthma

A

Patients >= 17 years
patients should be asked if their symptoms are better on days away from work/during holidays. If so, patients should be referred to a specialist as possible occupational asthma
all patients should have spirometry with a bronchodilator reversibility (BDR) test
all patients should have a FeNO test

Children 5-16 years
all children should have spirometry with a bronchodilator reversibility (BDR) test
a FeNO test should be requested if there is normal spirometry or obstructive spirometry with a negative bronchodilator reversibility (BDR) test

Patients < 5 years
- diagnosis should be made on clinical judgement

FeNO
in adults level of >= 40 parts per billion (ppb) is considered positive
in children a level of >= 35 parts per billion (ppb) is considered positive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Differentials of intermediate probability without airflow obstruction (from additional investigation)

A

-Chronic cough syndrome
-Hyperventilation
-Vocal cord dysfunction
-Rhinitis
-Gastroesophageal reflux
-Heart failure
-Pulmonary fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Differentials of intermediate probability WITH airflow obstruction (from additional investigation)

A

-COPD
-Bronchiectasis
-Inhaled foreign body
-Lung cancer
-Sarcoidosis
-Obliterative bronchiolitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Aims of asthma management/ control

A

-No daytime symptoms
-No nighttime awakening to asthma
-No need for rescue medications
-No exacerbations
-No limitations on activity including exercise
-Normal lung function (FEV1 and/or PEF>80% predicted or best)
=With minimal side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Non-pharmacological management

A

-Avoid/ remove provoking factors
=Aeroallergen
=Food allergen
=Tobacco smoke
=Obesity
=Aspirin/ b-blockers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Describe short-acting beta agonists

A

-Inhaled short-acting B2-agonist
=Salbutamol and terbutaline
=B2-adrenergic receptors
=Bronchodilator activity
=First-line, typically used if patient develops symptoms

-Relatively B2 selective but cardiac effects (B1)
=Tachycardia, vasodilation, arrhythmia. Relax smooth muscle of the airways
-Systemic effects
=Hypokalaemia, tremor, insomnia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Frequency and use of short-acting beta agonists

A

-Symptomatic asthma
-More than 3 doses a week= prompt review for moving to next step of therapy
-Prescribed more than 1 inhalers device a month should have assessed urgently
-Monotherapy only recommended for infrequent short-lived wheeze (usually exercise)

21
Q

Describe regular preventor therapy

A

-Inhaled corticosteroids- mainstay (beclomethasone 200mcg tds)
=Reduced inflammatory cell infiltration
=Reduced vascular permeability
=Upregulate B2 responsiveness on airway smooth muscle
=Used in patients where asthma is not controlled by SABA alone taken everyday regardless of symptoms (the preventer)

=Reduce bronchial hyperactivity
=Increase lung function and QOL
=Reduces symptoms
=Reduce exacerbations

-SE: oral candidiasis, stunted growth in children

22
Q

Frequency and use of regular preventor therapy

A

-Suspected asthma= low dose ICS for 6 weeks and assess response
-Diagnosed asthma- start at low dose appropriate to symptoms

23
Q

Describe initial add-on therapy

A

-A proportion of patients may not be adequately controlled at step 2
-Recheck compliance, inhaler technique, eliminate trigger factors

-Long-acting beta 2 agonists (salmeterol) to ICS over just increasing ICS dose
=Fostair (beclomethasone and formoterol)
=Relvar (fluticasone and vilanterol)
=Taken everyday regardless of symptoms

24
Q

Additional add-on therapy

A

-Leukotriene receptor antagonists to reduce:
=Smooth muscle contraction
=Oedema
=Increased vascular permeability
=Mucus stimulation/secretion
=Chemoattractant for eosinophils
=patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist, not a LABA
=MART is now an option for patients with poorly controlled asthma

-Theophylline
=Bronchodilator, adenosine antagonist? Raises intracellular cAMP? Numerous side effects

25
Q

What is MART?

A

-A form of combined ICS and LABA treatment in which a single inhaler, containing both ICS and a fast-acting LABA, is used for both daily maintenance therapy and the relief of symptoms as required
-MART is only available for ICS and LABA combinations in which the LABA has a fast-acting component (for example, formoterol)

26
Q

Flow chart of adult asthma management

A
  1. Newly diagnosed: SABA
  2. Not controlled/ symptoms >3x week or night time waking: SABA + low dose ICS
  3. SABA + low dose ICS + LTRA
  4. SABA + low dose ICS + LABA +/- LTRA
  5. SABA +/- LTRA + low-dose MART
  6. SABA +/- LTRA + medium dose MART/ moderate dose ICS + LABA
  7. SABA +/- LTRA + high dose ICS/ LAMA or theophylline
27
Q

Side effects of continuous or frequent oral steroids

A

-Weight gain
-Osteoporosis
-Hypertension
-Muscle weakness
-Skin thinning
-Cataracts
-Adrenal suppression

28
Q

Severe asthma treatment

A

-High dose inhaled corticosteroid
-Tiotropium
-Immunosuppressants
-Macrolide antibiotics
-Anti IgE (omalizumab)
-Anti IL-5 (mepolizumab)

29
Q

BTS guideline steps

A
  1. Monitored low dose ICS
  2. Add inhaled LABA (fixed dose or MART)
  3. Increasing ICS to medium dose or adding LTRA (if no response to LABA consider stopping it)
  4. Specialist therapies
30
Q

Stepping down asthma management

A

-Complete asthma control for at least 3 months
-Keep device changes to minimum
-Consider beclomethasone equivalence of different inhaler devices
-Review every 3 months
-Step-up if control lost
-When reducing the dose of inhaled steroids the BTS advise us to do this by 25-50% at a time.

31
Q

Definition of acute asthma exacerbations

A

-PEF<80% predicted/best
-Increased bronchodilator use
-Increased nocturnal symptoms
-Increased symptom scores
=For 2 or more consecutive days

-70% initiated by viral URTI

32
Q

Treatment of mild exacerbations

A

PEF>80%
=2-4 puffs B2 agonist 4 hourly

33
Q

Treatment of moderate exacerbations

A

PEF 50-80%
-High dose bronchodilators
=MDI via spacer: 4-6 puffs every 10-20 minutes
=Oxygen driven nebuliser
-Prednisolone 40mg 5 days

34
Q

Baseline severity history in acute asthma

A

-Recent hospital admission
-Three or more regular medications
-Frequent after-hours GP visits
-Psychosocial problems
-Previous ICU admission

35
Q

Acute severity history in acute asthma

A

-Heavy use of B2-agonist
-Marked (>50%) reduction or variation in peak flow
-Precipitant asthma

36
Q

General clinical examination of acute asthma

A

-General appearance
-RR
-Pulse

37
Q

Moderate acute asthma examination findings

A

-Speech normal
-RR <25 bpm
-Pulse <110 bpm
PEFR 50-75%

-Children 2-5: >92%, no clinical features of severe asthma
-Children >5: >92%, PEF>50%, no clinical features of severe asthma

38
Q

Severe acute asthma examination findings

A

-Cannot complete sentences
-RR >25
-Pulse >110
PEFR 33-50%

-Children aged 2-5: <92%, too breathless to talk or feed, HR >140, RR >40, use of accessory neck muscles
-Children>5: <2%, PEF 33-50%, can’t complete sentences in one breath or too breathless to talk or feed, HR >125, RR >30, use of accessory neck muscles

39
Q

Life-threatening acute asthma examination findings

A

-Silent chest, cyanosis, poor respiratory effort
-Bradycardia, dysrhythmia, hypotension
-Exhaustion, confusion, coma
-PEFR <33%, sats <92%, normal CO2 4.6-6)

=Type 2 hypercapnia state

-Children aged 2-5: <92%, silent chest, poor resp effort, agitation, altered consciousness, cyanosis
-Children >5: <92%, PEF<33%, silent, poor effort, altered consciousness, cyanosis

40
Q

Acute asthma assessment

A

-Lung function
=Spiro or PEF
-Expressed as % pred/best
-33-50% severe
-<33% life threatening

-Oxygenation
=Pulse oximetry
=ABG if spO2<92%

the BTS guidelines recommend arterial blood gases for patients with oxygen sats < 92%
a chest x-ray is not routinely recommended, unless:
life-threatening asthma
suspected pneumothorax
failure to respond to treatment

41
Q

Goals of immediate treatment of acute exacerbation

A

-Correction of hypoxemia
=High flow O2 (40-60%)
=Aim for sats >94%

-Rapid reversal of airflow obstruction
=Salbutamol MDI- spacer or O2 driven neb
=Add ipratropium (short acting muscarinic) if no response

-Reduction in likelihood of recurrence of severe airflow obstruction
=Prednisolone 40mg 5 days

42
Q

Magnesium sulphate as treatment

A

-Bronchodilator (acts as calcium channel
-Recommended if FEV1 <50% pred

43
Q

Asthmatic features that suggest strong steroid response

A

-previous diagnosis of asthma or atopy
-a higher blood eosinophil count
-substantial variation in FEV1 over time (at least 400 ml)
-substantial diurnal variation in peak expiratory flow (at least 20%)

44
Q

SIGN guidelines for escalating care in acute severe asthma

A
  1. Oxygen
  2. Salbutamol nebulisers
  3. Ipratropium bromide nebulisers (severe/life-threatening/no response)
  4. Hydrocortisone IV OR Oral Prednisolone 40-50mg PO daily (5 days/ recovery)
  5. Magnesium Sulfate IV (severe/life-threatening)
  6. Aminophylline/ IV salbutamol

Discharge
=been stable on their discharge medication (i.e. no nebulisers or oxygen) for 12-24 hours
inhaler technique checked and recorded
PEF >75% of best or predicted

45
Q

Children aged 5-16 management (stable)

A
  1. Newly diagnosed asthma: SABA
  2. Not controlled on previous step/ newly diagnosed with symptoms >3 a week or night-time waking: SABA + paediatric low-dose ICS
  3. SABA + paediatric low-dose ICS + LTRA
  4. SABA + paediatric low-dose ICS + LABA (stop LTRA if hasn’t helped)
  5. SABA + switch ICS/LABA for MART that included paediatric low-dose ICS
  6. SABA + paediatric moderate-dose ICS MART fixed-dose moderate-dose OCS and separate LABA
  7. SABA +high dose ICS (either fixed-dose or MART)/ theophylline/ resp referral
46
Q

Children aged below 5 (stable)

A
  1. Newly diagnosed: SABA
  2. Not controlled/ new with >3 symptoms or night-time waking: SABA + 8-week trial paediatric moderate dose ICS
    =If symptoms recur within 4 weeks, restart ICS low dose
    =If symptoms recur after 4 weeks, repeat trial
  3. SABA + low ICS + LTRA
  4. Stop LTRA and refer
47
Q

Management of children with mild to moderate acute asthma attack

A

Bronchodilator therapy
give a beta-2 agonist via a spacer (for a child < 3 years use a close-fitting mask)
give 1 puff every 30-60 seconds up to a maximum of 10 puffs
if symptoms are not controlled repeat beta-2 agonist and refer to hospital

Steroid therapy
should be given to all children with an asthma exacerbation
treatment should be given for 3-5 days
=2-5 yrs: 20 mg od
=>5yrs: 30-40 mg od

48
Q

Paediatric doses of ICS

A

<= 200 micrograms budesonide or equivalent = paediatric low dose
200 micrograms - 400 micrograms budesonide or equivalent = paediatric moderate dose
> 400 micrograms budesonide or equivalent= paediatric high dose.

49
Q

Adult doses of ICS

A

<= 400 micrograms budesonide or equivalent = low dose
400 micrograms - 800 micrograms budesonide or equivalent = moderate dose
> 800 micrograms budesonide or equivalent= high dose.